PT  - JOURNAL ARTICLE
AU  - Chatterjee, Emeli
AU  - Rodosthenous, Rodosthenis S.
AU  - Kujala, Ville
AU  - Karalis, Katia
AU  - Spanos, Michail
AU  - Lehmann, Helge Immo
AU  - de Oliveira, Getulio Pereira
AU  - Shi, Mingjian
AU  - Miller-Fleming, Tyne W
AU  - Li, Guoping
AU  - Gokulnath, Priyanka
AU  - Ghiran, Ionita Calin
AU  - Lindenfeld, JoAnn
AU  - Mosley, Jonathan D
AU  - Sheng, Quanhu
AU  - Shah, Ravi
AU  - Das, Saumya
TI  - Circulating Extracellular Vesicles in Human Cardiorenal Syndrome Promote Renal Injury
AID  - 10.1101/2023.02.07.23285599
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.07.23285599
4099  - http://medrxiv.org/content/early/2023/02/10/2023.02.07.23285599.short
4100  - http://medrxiv.org/content/early/2023/02/10/2023.02.07.23285599.full
AB  - Background Cardiorenal syndrome (CRS)—renal injury during heart failure (HF)—is linked to higher morbidity. Whether circulating extracellular vesicles (EVs) and their RNA cargo directly impact its pathogenesis remains unclear.Methods Using a microfluidic kidney chip model (KC), we investigated transcriptional effects of circulating EVs from patients with CRS on renal epithelial/endothelial cells. We used small RNA-seq on circulating EVs and regression to prioritize subsets of EV miRNAs associated with serum creatinine, a biomarker of renal function. In silico pathway analysis, human genetics, and interrogation of expression of miRNA target genes in the KC model and in a separate cohort of individuals post-renal transplant with microarray-based gene expression was performed for validation.Results Renal epithelial and endothelial cells in the KC model exhibited uptake of EVs. EVs from patients with CRS led to higher expression of renal injury markers (IL18, NGAL, KIM1) a greater cystatin C secretion relative to non-CRS EVs. Small RNA-seq and regression identified 15 miRNAs related to creatinine, targeting 1143 gene targets specifying pathways relevant to renal injury, including TGF-b and AMPK signaling. We observed directionally consistent changes in expression of TGF-b pathway members (BMP6, FST, TIMP3) in KC model exposed to CRS EVs, as well as in renal tissue after transplant rejection. Mendelian randomization suggested a role for FST in renal function.Conclusion EVs from patients with CRS directly elicit adverse transcriptional and phenotypic responses in a KC model by regulating biologically relevant pathways, suggesting a novel role for EVs in CRS.Trial Registration ClinicalTrials.gov NCT 03345446.Funding AHA (SFRN16SFRN31280008), NHLBI (1R35HL150807-01) and NCATS (UH3 TR002878).Competing Interest StatementSD is a founding member of Thryv Therapeutics and Switch Therapeutics with equity and consulting agreements, consulting agreement with Renovacor and research funding from Abbott and Bristol Myers Squib; none were relevant for this study. Dr. Shah is supported in part by grants from the National Institutes of Health and the American Heart Association. In the past 12 months, Dr. Shah has served as a consultant for Cytokinetics and has been on a scientific advisory board for Amgen. Dr. Shah is a co-inventor on a patent for ex-RNAs signatures of cardiac remodeling. VK is an employee of Emulate, Inc.Funding StatementAHA (SFRN16SFRN31280008), NHLBI (1R35HL150807-01) and NCATS (UH3 TR002878).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board at Mass General BrighamI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors